Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-010 in Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763Phase 1Active, not recruiting
- Sponsor
- Caribou Biosciences
- Start
- May 2021
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 3
01
Overview
Phase 1, open-label trial of vispacabtagene regedleucel in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Caribou Biosciences. Primary endpoints: Dose-Limiting Toxicities at 28 days and Tumor Response up to 12 months. Started May 2021; status: active, not recruiting.
02
Drugs
vispacabtagene regedleucel
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04637763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637763.